<s>[INST] The next text is a question of a member of the European parliament:"In its answer to Written Question E‑3717/2010, the Commission states that ‘botulinum toxin is widely used for aesthetic purpose through off-label use’. On 1September2010, theUS Department of Justice issued a press release stating that the pharmaceutical company Allergan Inc. (which produces the botulin‑based pharmaceutical Botox) had admitted liability and offered to pay USD600000 to end the legal action concerning prejudice arising from the promotion of Botox for purposes other than the intended therapeutic purposes (‘off-label promotion’). The answer from the Commission would seem to confirm that the toxin botulin has indeed been used improperly, and not for the purposes indicated, which is why such a large fine was imposed on the producer. The conclusion is that the use of Botox for purposes other than those indicated is damaging to anyone who uses it.  1.In the light of the above, can the Commission state whether is considers it sufficient to indicate that ‘Member States authorities may take measures to discourage the off-label use of such substance for aesthetic purpose …if they consider it appropriate.’   2.Would it not consider it effective to safeguard health via regulation within theEU of the use and sale of the botulin, along the lines of the justifications given by theUS Department of Justice in its decision?"
Analyze carefully the text and assign it to the most relevant policy area among those listed below. Do not explain your answer and return only a number.
Policy area numbers: 1 = Macroeconomics
2 = Civil Rights, Minority Issues and Civil Liberties
3 = Health
4 = Agriculture and Fisheries
5 = Labour, employment and pensions
6 = Education
7 = Environment
8 = Energy
9 = Immigration
10 = Transportation
12 = Law and Crime
13 = Social welfare
14 = Regional and Urban issues and Planning
15 = Banking, finance and domestic commerce issues
16 = Defence
17 = Space, science, technology, and communications issues
18 = Foreign trade
19 = International affairs and foreign aid
20 = Governance and government
21 = Public Lands, Water Management and Territorial Issues
23 = Culture and media
[/INST]. Answer = [3]. </s>
In its answer to Written Question E‑3717/2010, the Commission states that ‘botulinum toxin is widely used for aesthetic purpose through off-label use’. On 1September2010, theUS Department of Justice issued a press release stating that the pharmaceutical company Allergan Inc. (which produces the botulin‑based pharmaceutical Botox) had admitted liability and offered to pay USD600000 to end the legal action concerning prejudice arising from the promotion of Botox for purposes other than the intended therapeutic purposes (‘off-label promotion’). The answer from the Commission would seem to confirm that the toxin botulin has indeed been used improperly, and not for the purposes indicated, which is why such a large fine was imposed on the producer. The conclusion is that the use of Botox for purposes other than those indicated is damaging to anyone who uses it.  1.In the light of the above, can the Commission state whether is considers it sufficient to indicate that ‘Member States authorities may take measures to discourage the off-label use of such substance for aesthetic purpose …if they consider it appropriate.’   2.Would it not consider it effective to safeguard health via regulation within theEU of the use and sale of the botulin, along the lines of the justifications given by theUS Department of Justice in its decision?